BUENOS AIRES, July 30 (Xinhua) — Experts in viral diseases and infectology have highlighted the efficacy of Chinese vaccines against COVID-19 and its new variants.<\/p>\n\n\n\n
“According to the evidence available so far, vaccines that have been licensed by the World Health Organization (WHO) are effective against all variants in circulation globally,” Jairo Mendez Rico, adviser on emerging viral diseases to the Pan American Health Organization (PAHO), told Xinhua recently.<\/p>\n\n\n\n
The WHO gave emergency-use approval to the COVID-19 vaccines developed by Chinese companies Sinopharm and Sinovac in May and June respectively.<\/p>\n\n\n\n
“We need to highlight the notable impact that vaccination has had in reducing mortality, severe cases and hospitalizations, which are fundamental objectives for controlling the epidemic,” said the PAHO adviser.<\/p>\n\n\n\n
“That’s why, regardless of the variants in circulation, vaccines — along with all the public health measures that we already know about, including the use of a mask, physical distancing, isolating cases and quarantining contacts — continue to be the most efficient way to stop the transmission,” he added.<\/p>\n\n\n\n
He also said that vaccines are not one hundred percent effective, “therefore we will always have several cases of people who are going to get infected, even if they are fully vaccinated.”<\/p>\n\n\n\n
The COVID-19 vaccine developed by Sinopharm is 84 percent effective in preventing deaths caused by the disease, according to a recent report from Argentina’s Ministry of Health.<\/p>\n\n\n\n
The document, titled “Study of the National Vaccination Campaign’s Effectiveness in Reducing Mortality from COVID-19 in People aged 60 and over,” was prepared by the ministry with cases from the country’s 24 provinces during the period from Jan. 1 to June 22.<\/p>\n\n\n\n
The effectiveness against COVID-19 mortality in the Sinopharm vaccine reached 61.6 percent with the application of the first dose in the 147,908 cases analyzed, and increased to 84 percent after the second dose was applied to the same number of people.<\/p>\n\n\n\n
Argentina in February authorized the emergency use of the Sinopharm vaccine after Health Minister Carla Vizzotti signed a resolution, an official measure which highlighted the “safety, immunogenicity and efficacy” of the vaccine.<\/p>\n\n\n\n
In June, Argentina approved the emergency use of the vaccine developed by China’s CanSino Biologics.<\/p>\n\n\n\n
Both the Sinopharm and CanSino vaccines were “effective,” Argentine infectious diseases expert Martin Hojman said in a recent interview with Xinhua, adding that their arrival in the South American country was “excellent news.”<\/p>\n\n\n\n
“The Sinopharm has two doses. It is an inactivated vaccine that has proven efficacy and has no adverse effects. It is a safe vaccine,” said Hojman.<\/p>\n\n\n\n
“The CanSino has the advantage of being a single dose, it also has very good efficacy, and can be stored in normal cold (storage) for a long time, so it is an easier vaccine,” Hojman added. <\/p>\n\n\n\n
Source: http:\/\/www.xinhuanet.com\/english\/2021-07\/30\/c_1310097018.htm<\/p>\n\n\n\n
<\/p>","protected":false},"excerpt":{"rendered":"
BUENOS AIRES, July 30 (Xinhua) — Experts in viral diseases and infectology have highlighted the efficacy of Chinese vaccines against COVID-19 and its new variants. “According to the evidence available so far, vaccines that have been licensed by the World Health Organization (WHO) are effective against all variants in circulation […]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_newsletter_tier_id":0,"jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[1],"tags":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":2401,"url":"https:\/\/www.govisachina.com\/zh\/2021\/07\/13\/providing-500-mln-vaccine-doses-to-world-china-aims-to-enhance-intl-cooperation-against-covid-19\/","url_meta":{"origin":2421,"position":0},"title":"Providing 500 mln vaccine doses to world, China aims to enhance int’l cooperation against COVID-19","author":"Visa China","date":"7\u6708 13, 2021","format":false,"excerpt":"BEIJING, July 13 (Xinhua) -- Chinese vaccines are gathering steam across the world, injecting strong impetus into the global fight against COVID-19 as deaths from the virus topped 4 million worldwide and variants spread to more than 100 countries. As a steadfast advocate for equitable vaccine distribution around the globe,\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2439,"url":"https:\/\/www.govisachina.com\/zh\/2021\/08\/06\/xinhua-headlines-china-is-keeping-its-word-in-building-global-immunity-barrier\/","url_meta":{"origin":2421,"position":1},"title":"Xinhua Headlines: China is keeping its word in building global immunity barrier","author":"Visa China","date":"8\u6708 6, 2021","format":false,"excerpt":"BEIJING, Aug. 5 (Xinhua) -- China will strive to provide 2 billion COVID-19 vaccine doses to the world throughout this year and offer 100 million U.S. dollars to COVAX, Chinese President Xi Jinping said here Thursday, marking a further step by China in honoring its commitment to making vaccines a\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2180,"url":"https:\/\/www.govisachina.com\/zh\/2021\/05\/06\/third-wave-of-covid-19-inevitable-in-india-says-principal-scientific-advisor\/","url_meta":{"origin":2421,"position":2},"title":"Third wave of COVID-19 inevitable in India, says principal scientific advisor","author":"Visa China","date":"5\u6708 6, 2021","format":false,"excerpt":"By Xinhua NEW DELHI -- A third wave of COVID-19 outbreak is inevitable in India given the higher levels of the circulating virus, said Principal Scientific Advisor to India's Federal Government K. Vijay Raghavan on Wednesday. \"But it is not clear on what time scale this phase three will occur.\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/05\/60933bb9a31024adbdc61241.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/05\/60933bb9a31024adbdc61241.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/05\/60933bb9a31024adbdc61241.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/05\/60933bb9a31024adbdc61241.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/05\/60933bb9a31024adbdc61241.jpeg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":2190,"url":"https:\/\/www.govisachina.com\/zh\/2021\/05\/10\/who-approval-of-sinopharm-vaccine-set-to-benefit-world-coronavirus-fight\/","url_meta":{"origin":2421,"position":3},"title":"WHO approval of Sinopharm vaccine set to benefit world coronavirus fight","author":"Visa China","date":"5\u6708 10, 2021","format":false,"excerpt":"By BO LEUNG in London The World Health Organization's approval to give emergency use to the COVID-19 vaccine manufactured by China's Sinopharm has been welcomed by experts and health regulators worldwide. On Friday, the WHO gave the vaccine the green light, paving the way for potentially millions of doses to\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2449,"url":"https:\/\/www.govisachina.com\/zh\/2021\/08\/16\/contributions-to-covax-reflect-chinas-commitment-to-global-anti-covid-19-fight-bangladesh-health-experts\/","url_meta":{"origin":2421,"position":4},"title":"Contributions to COVAX reflect China’s commitment to global anti-COVID-19 fight: Bangladesh health experts","author":"Visa China","date":"8\u6708 16, 2021","format":false,"excerpt":"DHAKA, Aug. 12 (Xinhua) -- China's contributions through the COVAX Facility have reflected Beijing's commitment to global anti-COVID-19 fight, Bangladesh health experts said. They expressed appreciation of China's contributions after Bangladesh Tuesday night received 1.7 million Chinese COVID-19 vaccine doses shipped via the COVAX Facility. This is the first among\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2314,"url":"https:\/\/www.govisachina.com\/zh\/2021\/06\/02\/who-validates-chinas-sinovac-covid-19-vaccine-for-emergency-use\/","url_meta":{"origin":2421,"position":5},"title":"WHO validates China’s Sinovac COVID-19 vaccine for emergency use","author":"Visa China","date":"6\u6708 2, 2021","format":false,"excerpt":"GENEVA, June 1 (Xinhua) The World Health Organization (WHO) validated on Tuesday the CoronaVac COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac for emergency use. \"I am happy to announce that the Sinovac coronavirus vaccine has been given WHO Emergency Use Listing (EUL) after being found to be safe, effective,\u2026","rel":"","context":"\u5728\u201cCOVID-19\u201d\u4e2d","block_context":{"text":"COVID-19","link":"https:\/\/www.govisachina.com\/zh\/category\/covid-19\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/www.govisachina.com\/wp-content\/uploads\/2021\/06\/vaccine-5895477_1920.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/posts\/2421"}],"collection":[{"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/comments?post=2421"}],"version-history":[{"count":1,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/posts\/2421\/revisions"}],"predecessor-version":[{"id":2422,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/posts\/2421\/revisions\/2422"}],"wp:attachment":[{"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/media?parent=2421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/categories?post=2421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.govisachina.com\/zh\/wp-json\/wp\/v2\/tags?post=2421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}